Senti Biosciences
Model SENTI-202 - Acute Myeloid Leukemia Cells
Pursuing an Unmet Need in the Treatment of AML - SENTI-202 is designed to target and eliminate acute myeloid leukemia cells while sparing healthy bone marrow. Our vision is a potential medicine that does not rely on an invasive bone marrow transplant.
Most popular related searches
acute myeloid leukemia
bone marrow transplantation
myeloid leukemia
bone marrow
natural killer cell therapy
acute leukemia
natural killer cell
immune system
leukemia
cell therapy
Logic Gated Allogeneic CAR-NK Cell Therapy for AML
The unique product profile of SENTI-202 has the potential to drive towards a cure for AML without the need for a bone marrow transplant by enabling killing of diverse AML cells while sparing healthy stem cells that regenerate the blood and the immune systems.